Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech success, 2002 -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (27)	2/23/2002 12:37:35 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 117

That Remicade/Enbrel (most notably Enbrel) will be serious competitor to DNA/BGEN new psoriasis drug was very predictive 12 months ago. Again, surprise hit street. And BGEN rise 2 points??? Friday February 22, 9:15 am Eastern Time Press Release SOURCE: Robert Wood Johnson Medical School Positive Results From ENBREL(R) (etanercept) Monotherapy Psoriasis Study to be Presented by RWJMS Researcher at American Academy of Dermatology Conference NEW BRUNSWICK, N.J., Feb. 22 /PRNewswire/ -- Alice Gottlieb, MD, Ph.D., Professor of Medicine at the University Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School, will present results from a Phase 2 clinical study of ENBREL® (etanercept) for the treatment of psoriasis at the 60th Annual American Academy of Dermatology Conference in New Orleans. The study demonstrated that 56% of patients treated with ENBREL had at least a 75% improvement in their psoriasis over the six month period compared to 5% of patients receiving placebo. ENBREL was approved by the U.S. Food and Drug Administration (FDA) last month to treat psoriatic arthritis a disease with both joint and skin involvement. ``We previously have seen the effectiveness of ENBREL on the psoriatic plaques of psoriatic arthritis patients,'' said Gottlieb. ``This new psoriasis study provides data that show ENBREL, used without other medicines, may be a powerful new weapon against this life-impacting disease.'' Patients treated with ENBREL in this study experienced a significant improvement at 3 months, with 30 % of patients on ENBREL achieving PASI 75, compared with 2% of those on placebo (p < 0.0001). Continued improvement was seen throughout the study. After six months of treatment, 56% of patients receiving ENBREL achieved PASI 75, compared with 5% of those receiving placebo at six months. Additionally, 21% of patients receiving ENBREL achieved PASI 90 compared to none of the patients who received placebo. <snip>